The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Anti-LGI1–associated cognitive impairment: Presentation and long-term outcome
Open accessAbstract
OBJECTIVE: We investigated a series of patients with LGI1 antibody (Ab)-related cognitive deterioration to determine the clinical presentation, long-term outcome, and LGI1 Ab evolution. METHODS: We retrospectively analyzed the clinical information of 76 patients with LGI1 Ab-related cognitive deterioration. Presenting syndromes were classified as limbic encephalitis (LE), non-LE, or encephalopathy (normal MRI and no CSF pleocytosis). Frequency of relapses and clinical outcome were assessed in 48 patients with prolonged follow-up (median 39 months, range 18-200). RESULTS: Sixty-three patients (83%) developed LE, 3 (4%) non-LE, and 10 (13%) encephalopathy. All patients received steroids, IV immunoglobulins (Ig), or both. At 2 years, 17 (35%; 95% CI 21%-49%) fully recovered, 17 (35%) became functionally independent but not at baseline or were unable to return to work, 11 (23%) required assistance because of moderate or severe cognitive deficits, and 3 (6%) died. Predictors of bad outcome included no response to initial immunotherapy (odds ratio 23.0, 95% CI 2.4-215.6, p = 0.006) and clinical relapses (odds ratio 10.2, 95% CI 1.0-100.1, p = 0.047) that occurred in 13 patients (27%). In all patients, the LGI1 Abs were IgG4 and usually detectable in both serum and CSF (only CSF, 8%). Abs remained positive in serum of 4 of 16 patients with long-term follow-up; 3 of these 4 patients fully recovered and none showed class switch to IgG1. CONCLUSIONS: Up to 13% of patients with LGI1 Abs develop cognitive impairment without criteria of encephalitis. After immunotherapy, only 35% of patients return to their baseline cognitive function. Serum LGI1 Abs may remain detectable after full clinical recovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A clinical approach to diagnosis of autoimmune encephalitis
Graus, F., Titulaer, M. J., Balu, R., Benseler, S., Bien, C. G., Cellucci, T., Cortese, I., Dale, R. C., Gelfand, J. M., Geschwind, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00401-9 · Cited by 4,516
Self-citationTitulaer, M. J., McCracken, L., Gabilondo, I., Armangué, T., Glaser, C., Iizuka, T., Honig, L. S., Benseler, S. M., Kawachi, I., Martinez-Hernandez, E., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70310-1 · Cited by 3,165 · cited 1×
“Taken together, these data suggest that patients who do not respond or worsen during firstline immunotherapy should receive second-line immunotherapy, as shown in patients with antiNMDAR encephalitis.(11) Rituximab has been considered particularly effective in IgG4-mediated disorders(9) but there are limited data for…”
BackgroundSelf-citationLai, M., Huijbers, M. G., Lancaster, E., Graus, F., Bataller, L., Balice-Gordon, R., Cowell, J. K., & Dalmau, J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70137-x · Cited by 1,361
Self-citationIrani, S. R., Alexander, S., Waters, P., Kleopa, K. A., Pettingill, P., Zuliani, L., Peles, E., Buckley, C., Lang, B., & Vincent, A. (2010) · Brain · doi:10.1093/brain/awq213 · Cited by 1,359
Gresa-Arribas, N., Titulaer, M. J., Torrents, A., Aguilar, E., McCracken, L., Leypoldt, F., Gleichman, A. J., Balice-Gordon, R., Rosenfeld, M. R., Lynch, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70282-5 · Cited by 1,306
Self-citationVincent, A., Buckley, C., Schott, J. M., Baker, I., Dewar, B., Detert, N., Clover, L., Parkinson, A., Bien, C. G., Omer, S., et al. (2004) · Brain · doi:10.1093/brain/awh077 · Cited by 1,038
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis
Irani, S. R., Michell, A. W., Lang, B., Pettingill, P., Waters, P., Johnson, M. R., Schott, J. M., Armstrong, R. J. E., S. Zagami, A., Bleasel, A., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22307 · Cited by 928
Morvan syndrome: Clinical and serological observations in 29 cases
Irani, S. R., Pettingill, P., Kleopa, K. A., Schiza, N., Waters, P., Mazia, C., Zuliani, L., Watanabe, O., Lang, B., Buckley, C., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23577 · Cited by 540
Ohkawa, T., Fukata, Y., Yamasaki, M., Miyazaki, T., Yokoi, N., Takashima, H., Watanabe, M., Watanabe, O., & Fukata, M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3506-13.2013 · Cited by 357
Imaging of autoimmune encephalitis – Relevance for clinical practice and hippocampal function
Heine, J., Prüss, H., Bartsch, T., Ploner, C. J., Paul, F., & Finke, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.037 · Cited by 272
Cited by
Antibody-Mediated Encephalitis
Dalmau, J., & Graus, F. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1708712 · Cited by 1,329
Self-citationDalmau, J., Geis, C., & Graus, F. (2017) · Physiological Reviews · doi:10.1152/physrev.00010.2016 · Cited by 628
Self-citationThe value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis
van Sonderen, A., Petit-Pedrol, M., Dalmau, J., & Titulaer, M. J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.43 · Cited by 272
Self-citationTreatment strategies for autoimmune encephalitis
Shin, Y.-W., Lee, S.-T., Park, K.-I., Jung, K.-H., Jung, K.-Y., Lee, S. K., & Chu, K. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722347 · Cited by 266
Steriade, C., Britton, J., Dale, R. C., Gadoth, A., Irani, S. R., Linnoila, J., McKeon, A., Shao, X., Venegas, V., & Bien, C. G. (2020) · Epilepsia · doi:10.1111/epi.16571 · Cited by 265
Metadata
- Authors
- Ariño, H., Armangué, T., Petit-Pedrol, M., Sabater, L., Martinez-Hernandez, E., Hara, M., Lancaster, E., Saiz, A., Dalmau, J., & Graus, F.
- Venue
- Neurology
- Published
- 2016-08-23
- Volume
- 87
- Issue
- 8
- Pages
- 759-765
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2505174081
- Cited by
- 348
- References
- 19
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-LGI1–associated cognitive impairment: Presentation and long-term outcome. https://app.cochat.ai/papers/10.1212/wnl.0000000000003009
- The paper
- Ariño, H., Armangué, T., Petit-Pedrol, M., Sabater, L., Martinez-Hernandez, E., Hara, M., Lancaster, E., Saiz, A., Dalmau, J., & Graus, F. (2016). Anti-LGI1–associated cognitive impairment: Presentation and long-term outcome. Neurology. https://doi.org/10.1212/wnl.0000000000003009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.